These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. The effect of 1alpha-hydroxyvitamin D3 on calcium and mineral content of bone in renal osteodystrophy. Junor BJ; Catto GR Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():131s-138s. PubMed ID: 606411 [TBL] [Abstract][Full Text] [Related]
5. 1,25-dihydroxycholecalciferol in renal osteodystrophy. Epiphysiolysis--anticonvulsant therapy. Pierides AM; Ellis HA; Dellagrammatikas H; Scott JE; Norman AW Arch Dis Child; 1977 Jun; 52(6):464-72. PubMed ID: 879832 [TBL] [Abstract][Full Text] [Related]
6. [Long-term effects of a combination of 25-hydroxycholecalciferol and 1-alpha-hydroxycholecalciferol on osteodystrophy in chronic hemodialysis patients]. Sebert JL; Marie A; Kuntz D; Marie P; Gueris J; Smadja A; Fournier A; Quichaud J Rev Rhum Mal Osteoartic; 1981; 48(7-9):535-41. PubMed ID: 7291931 [TBL] [Abstract][Full Text] [Related]
8. The treatment of renal osteodystrophy with 1-alpha-hydroxycholecalciferol. Junor BJ; Catto GR; Macleod M Calcif Tissue Res; 1977 May; 22 Suppl():112-6. PubMed ID: 912512 [No Abstract] [Full Text] [Related]
9. The effect of 1alpha-hydroxyvitamin D3 in pre-dialysis renal bone disease. Pierides AM; Ellis HA; Simpson W; Cook D; Kerr DN Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():109s-116s. PubMed ID: 606409 [TBL] [Abstract][Full Text] [Related]
10. [Renal osteodystrophy in two children : a comparison of the effects of 1 alpha-hydroxycholecalciferol (author's transl)]. Chantraine JM; Davin JC; Lambrechts L; Heynen G Ann Endocrinol (Paris); 1979; 40(2):161-2. PubMed ID: 475307 [TBL] [Abstract][Full Text] [Related]
11. Histopathology of renal osteodystrophy with particular reference to the effects of 1alpha-hydroxyvitamin D3 in patients treated by long-term haemodialysis. Ellis HA; Pierides AM; Feest TG; Ward MK; Kerr DN Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():31s-38s. PubMed ID: 606422 [TBL] [Abstract][Full Text] [Related]
12. Serum alkaline phosphatase in azotemic and hemodialysis osteodystrophy: a study of isoenzyme patterns, their correlation with bone histology, and their changes in response to treatment with 1alphaOHD3 and 1,25(OH)2D3. Pierides AM; Skillen AW; Ellis HA J Lab Clin Med; 1979 Jun; 93(6):899-909. PubMed ID: 438610 [TBL] [Abstract][Full Text] [Related]
13. Whole-body in-vivo neutron activation analysis in assessing treatment of renal osteodystrophy with 1-alpha-hydroxycholecalciferol. Naik RB; Gosling P; Price CP; Robinson BH; Dabek JT; Heath DA; James HM; Kanis JA; Smith R Br Med J; 1976 Jul; 2(6027):79-83. PubMed ID: 1276820 [TBL] [Abstract][Full Text] [Related]
14. 1alpha-hydroxycholecalciferol: a promising therapeutic approach for renal osteodystrophy. Gotloib L; Mines M; Mazur Y; Sklan D; Garmizo AL; Jancu J; Israeli M; Malul M Isr J Med Sci; 1978 Jul; 14(7):731-5. PubMed ID: 681163 [TBL] [Abstract][Full Text] [Related]
15. Current status of the use of 1,25(OH)2D3 in the management of renal osteodystrophy. Massry SG; Goldstein DA; Malluche HH Kidney Int; 1980 Oct; 18(4):409-18. PubMed ID: 7014981 [No Abstract] [Full Text] [Related]